Akebia's Vadadustat Misses In Non-Dialysis CKD, But Filings Still Planned For 2021

 
• By Jessica Merrill

HIF-PHI inhibitor failed to show non-inferiority to ESAs in the primary cardiovascular safety endpoint of a Phase III program for the treatment of anemia due to chronic kidney disease.

Kidney Disease - Printed Diagnosis with Red Pills, Injections and Syringe. Medical Concept with Selective Focus.
Akebia hoped vadadustat would show a safety benefit in non-dialysis CDK versus ESAs • Source: Shutterstock

More from Genitourinary

More from Therapy Areas